Been digging into the psychedelic therapy space lately and there's actually some interesting stuff happening here that most people are sleeping on.

So here's the thing - while everyone's focused on cannabis, there's a whole other wave of alternative medicine trying to break through regulatory barriers. We're talking psilocybin, ketamine, LSD compounds that are finally getting serious clinical attention for treating depression and mental health disorders.

A few companies went public riding that hype wave a couple years back, saw their valuations spike, then got absolutely crushed in a selloff. But that dip might be exactly when some of these plays get interesting.

Take Atai Life Sciences for example. They're basically the broad bet on this space - researching multiple ketamine and psilocybin-based drugs at once. Their lead candidate COMP360 is in Phase 3 trials. Sure, they're burning cash on R&D, but that's actually how you get breakthroughs. When one of these drugs hits FDA approval, the upside could be massive.

Then you've got Compass Pathways, which is basically the focused play - all in on COMP360. Their Phase IIb data showed 20% of treatment-resistant depression patients had sustained improvement by week 12. For people who already failed traditional antidepressants, that's solid. The stock trades cheap right now, but it's basically a binary bet on FDA approval.

Cybin's another one trading in penny stock territory. They're developing multiple psilocybin therapies and actually got FDA breakthrough designation for their deuterated psilocybin program for major depressive disorder. The risk is higher here since they're still pre-revenue, but if their research pays off, the returns could be insane.

The real question is whether these ketamine and psilocybin therapies actually become the next big pharma category. Studies keep showing these compounds work for treatment-resistant depression when dosed right. It's just a matter of time and regulatory approval.

Not saying go all-in on any of these, but they're worth tracking if you're thinking about where mental health treatment is heading. The space is still early and most people don't realize how serious the clinical evidence is getting.